Oral microbiota dysbiosis, particularly in periodontitis, represents a significant yet under-recognized contributor to systemic bone loss and heightened osteoporosis risk. Disruption of the symbiotic oral microbial community permits pathobiont expansion, notably Porphyromonas gingivalis triggering chronic gingival inflammation. This local inflammatory milieu drives alveolar bone resorption through receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated osteoclastogenesis and matrix metalloproteinase activation. Notably, these pathological processes extend beyond the oral cavity by three interconnected mechanisms of hematogenous dissemination of periodontal pathogens and their virulence factors, which directly stimulate osteoclast differentiation in distant skeletal sites and by systemic spillover of pro-inflammatory cytokines, amplifying bone-resorptive signaling throughout the skeleton, across with dysregulation of the gut-bone axis, as oral pathobionts translocate to the gastrointestinal tract, altering gut permeability and microbiome composition to further exacerbate inflammatory bone loss. Epidemiological studies consistently associate periodontitis with reduced bone mineral density and increased fracture incidence, independent of traditional osteoporosis risk factors. Animal models confirm that oral pathogen challenge accelerates trabecular bone loss in long bones and vertebrae. These findings position oral dysbiosis as a modifiable risk factor for osteoporosis, suggesting that periodontal therapy and microbiome-targeted interventions may offer adjunctive strategies for skeletal health preservation. Future research should prioritize longitudinal human studies to establish causality and evaluate whether periodontal treatment attenuates systemic bone loss trajectories in at-risk populations.
Maternal primary hyperparathyroidism (PHPT), though rare during pregnancy, poses significant and disproportionate risks to the fetus and newborn due to transplacental passage of maternal calcium and parathyroid hormone (PTH). This condition disrupts the fetal mineral regulatory milieu, establishing a critical pathophysiological sequence. Sustained maternal hypercalcemia directly suppresses the development and function of the fetal parathyroid glands in utero, inducing a state of functional dependence on the maternal hypercalcemic environment for calcium homeostasis. Consequently, at delivery, the abrupt termination of both the maternal hypercalcemic drive and placental calcium transfer precipitates a high-risk period for the neonate. The infant, born with profoundly suppressed parathyroid reserve, faces a substantial challenge in mounting an adequate PTH secretory response to the sudden drop in calcium supply. This pathophysiological lag universally triggers neonatal hypocalcemia, the severity and duration of which are intrinsically linked to the depth and chronicity of in utero parathyroid suppression, as well as the individual neonate’s capacity for parathyroid functional recovery. Clinical manifestations can range from asymptomatic biochemical hypocalcemia to severe, life-threatening complications including seizures, tetany, apnea, and cardiomyopathy. Understanding this mechanistic pathway, from maternal hypercalcemia to fetal gland suppression and the predictable postnatal hypocalcemic crisis is paramount. It underscores the necessity for vigilant prenatal diagnosis of maternal PHPT, meticulous intrapartum planning, and intensive, protocol-driven neonatal monitoring and calcium/active vitamin D replacement strategies to prevent significant neonatal morbidity. Early recognition of this iatrogenic dependence is crucial for optimizing outcomes in affected offspring.
Pediatric obesity is characterized by a bidirectional metabolic dysregulation of vitamin D metabolism within adipose tissue, creating a state of functional deficiency that standard serum measurements often underestimate. Expanded adipose mass acts as a volumetric sink, sequestering fat-soluble vitamin D metabolites and contributing to low circulating 25-hydroxyvitamin D levels, inversely correlated with body fat. Crucially, adipose tissue inflammation drives profound local metabolic disruption, where pro-inflammatory cytokines (TNF-α, IL-6) down-regulate the activating enzyme CYP27B1 (1α-hydroxylase) and upregulate the degrading enzyme CYP24A1 (24-hydroxylase) in adipocytes and macrophages. This ‘double hit’ severely diminishes 1,25-dihydroxyvitamin D [1,25(OH)2D] within the adipose microenvironment, impairing vitamin D receptor (VDR) signaling precisely where it is needed to suppress inflammation. Systemic inflammation further compromises vitamin D status by reducing hepatic CYP2R1 activity, limiting the conversion of vitamin D to 25(OH) D. Additionally, obesity-associated alterations in vitamin D-binding protein (DBP) levels and isoforms may reduce the bioavailable (free) fraction of vitamin D metabolites, exacerbating tissue-level deficiency despite potentially borderline total serum 25(OH)D. Consequently, the combination of sequestration, inflammation-induced dysregulation of activating/degrading enzymes, and altered binding protein dynamics creates a significant disconnect, where standard serum 25(OH)D levels fail to reflect the critical local deficiency of bioactive vitamin D within the inflamed adipose tissue of obese children. This tissue-specific functional deficiency, driven by inflammation, underpins the impaired immunomodulation and perpetuates metabolic dysfunction, highlighting the inadequacy of conventional vitamin D assessment in obesity and necessitating consideration of bioavailability and tissue metabolism.
Recent findings detected a dynamic, reciprocal relationship between bone remodeling and cardiac dysfunction, significantly influencing atherosclerosis pathogenesis. The bone-heart axis consists of bidirectional signaling of bone-derived factors and dysregulated mineral metabolism, which directly affect vascular calcification, endothelial function, and myocardial stress. Conversely, cardiac hormones and systemic inflammation modulate osteoclast/osteoblast activity. Critically, shared molecular pathways, like RANKL/RANK/OPG modulate both skeletal turnover and vascular inflammation/calcification. Pathological bone resorption releases calcium and matrix vesicles that nucleate vascular calcification, accelerating atherosclerotic plaque instability. Reimagining this axis emphasizes on osteo-immunological mechanisms with central role in cardiovascular disease progression, suggesting integrated therapeutic targets for atherosclerosis beyond traditional lipid-centric approaches.
Primary hyperparathyroidism (PHPT), characterized by chronic parathyroid hormone (PTH) excess and sustained hypercalcemia, disrupts the oral environment by intricate systemic-oral interactions. Hypercalcemia alters salivary composition, viscoelasticity, and flow rate, impairing its antimicrobial properties while promoting bacterial adhesion and calcified plaque formation. These changes foster pathogenic microbial colonization and hasten dental calculus deposition. Concurrently, excess PTH directly triggers osteoclastic resorption in alveolar bone, amplifies proinflammatory cytokines, and boosts matrix metalloproteinases, culminating in periodontal destruction and dysbiosis. Clinically, patients experience heightened tooth mobility, accelerated periodontitis, increased caries risk, and oral discomfort. This oral dysbiosis-inflammation axis further elevates systemic inflammatory burden, exacerbating PHPT-related cardiovascular, metabolic, and renal comorbidities. The interplay between PTH-mediated endocrine dysregulation and oral microbiome shifts highlights the imperative for integrated care. Dentists serve as early detectors of subtle oral signs potentially unmasking undetected PHPT, while endocrinologists must incorporate routine dental assessments. Best results arise from collaborative strategies, including intensive preventive dentistry, meticulous oral hygiene, regular surveillance, and parathyroidectomy when warranted, to interrupt this vicious cycle and reestablish oral and systemic equilibrium.
